Reed Mark A.,Wood Thomas K.,Banfield Scott C.,Barden Christopher J.
申请号：
NZ70516713
公开号：
NZ705167A
申请日:
2013.08.22
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
In general, among other things, compounds of Formula I are provided: in which R11 is selected from the group consisting of benzylamino, N-methylbenzylamino, morpholino, thiomorpholino, pyrrolidino, etc. R13 is selected from the group consisting of 3-(1-ethanol-2-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, etc. and R12 and R14 are each independently hydrogen or alkyl. The compounds may be used to prevent or reduce the speed of oligomerization or aggregation of amyloid proteins, such as in diseases impacted, or caused, by amyloidosis. Methods of treatment are also provided.
